Laropiprant
This prostaglandin D2 receptor antagonist was developed to reduce the uncomfortable skin flushing that commonly occurs when people take niacin (a cholesterol-lowering vitamin). It was used in combination with extended-release niacin to improve patient tolerability, but was ultimately withdrawn after clinical trials showed no cardiovascular benefit.
Molekularmasse
435,9000 g/mol
LogP
3,50
TPSA
84,80 Ų
Lipinski-Regel der Fünf
Bestanden
Therapeutische Bereiche
Wirkmechanismus
Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.
2D-Struktur
Cite this structure
Embed this structure
SMILES
CS(=O)(=O)c1cc(F)cc2c3c(n(Cc4ccc(Cl)cc4)c12)[C@@H](CC(=O)O)CC3
InChI
InChI=1S/C21H19ClFNO4S/c1-29(27,28)18-10-15(23)9-17-16-7-4-13(8-19(25)26)20(16)24(21(17)18)11-12-2-5-14(22)6-3-12/h2-3,5-6,9-10,13H,4,7-8,11H2,1H3,(H,25,26)/t13-/m1/s1
Molecular Formula
C21H19ClFNO4S
HBD / HBA
1 / 5
Rotierbare Bindungen
5
Schwere Atome
29
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Häufig gestellte Fragen
This prostaglandin D2 receptor antagonist was developed to reduce the uncomfortable skin flushing that commonly occurs when people take niacin (a cholesterol-lowering vitamin). It was used in combination with extended-release niacin to improve patient tolerability, but was ultimately withdrawn after clinical trials showed no cardiovascular benefit.
Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.
Yes, Laropiprant is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL426559. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 9867642. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Medizinischer Haftungsausschluss
This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="laropiprant"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/laropiprant/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/laropiprant/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/laropiprant/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="laropiprant"></drugfyi-drug>